366 related articles for article (PubMed ID: 31447840)
1. Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Ghiringhelli F; Fumet JD
Front Immunol; 2019; 10():1816. PubMed ID: 31447840
[TBL] [Abstract][Full Text] [Related]
2. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
Tintelnot J; Stein A
World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
[TBL] [Abstract][Full Text] [Related]
4. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy.
Ciardiello D; Vitiello PP; Cardone C; Martini G; Troiani T; Martinelli E; Ciardiello F
Cancer Treat Rev; 2019 Jun; 76():22-32. PubMed ID: 31079031
[TBL] [Abstract][Full Text] [Related]
7. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Zhao P; Li L; Jiang X; Li Q
J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
[TBL] [Abstract][Full Text] [Related]
8. Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.
Llosa NJ; Luber B; Siegel N; Awan AH; Oke T; Zhu Q; Bartlett BR; Aulakh LK; Thompson ED; Jaffee EM; Durham JN; Sears CL; Le DT; Diaz LA; Pardoll DM; Wang H; Housseau F; Anders RA
Cancer Immunol Res; 2019 Oct; 7(10):1574-1579. PubMed ID: 31439614
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
[TBL] [Abstract][Full Text] [Related]
10. Hypermutated Tumors and Immune Checkpoint Inhibition.
Ciombor KK; Goldberg RM
Drugs; 2018 Feb; 78(2):155-162. PubMed ID: 29350327
[TBL] [Abstract][Full Text] [Related]
11. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.
Yaghoubi N; Soltani A; Ghazvini K; Hassanian SM; Hashemy SI
Biomed Pharmacother; 2019 Feb; 110():312-318. PubMed ID: 30522017
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of Colon Cancer.
Stein A; Folprecht G
Oncol Res Treat; 2018; 41(5):282-285. PubMed ID: 29705788
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances.
Vranic S
Bosn J Basic Med Sci; 2017 Aug; 17(3):274-275. PubMed ID: 28812534
[No Abstract] [Full Text] [Related]
14. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
Thomas J; Leal A; Overman MJ
Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
[TBL] [Abstract][Full Text] [Related]
15. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
Lin EM; Gong J; Klempner SJ; Chao J
World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
[TBL] [Abstract][Full Text] [Related]
16. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
18. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
[TBL] [Abstract][Full Text] [Related]
19. The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.
Garcia C; Ring KL
Curr Treat Options Oncol; 2018 Nov; 19(12):70. PubMed ID: 30397772
[TBL] [Abstract][Full Text] [Related]
20. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy.
Yi B; Cheng H; Wyczechowska D; Yu Q; Li L; Ochoa AC; Riker AI; Xi Y
Mol Cancer Ther; 2021 Jul; 20(7):1295-1304. PubMed ID: 33879557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
